SPRY
ARS Pharmaceuticals, Inc.Company with tickers: SPRY
CIK
1671858
CUSIP
82835W108
Shares Outstanding
99,303,262
13F Activity (30d)
134 filings
129 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $22,681,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $82,826,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $4,336,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-60,145,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-60,618,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.61 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.61 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |